Healthcare · NSE: SUNPHARMA
Intrynsic's multi-model valuation estimates Sun Pharmaceutical Industries Limited's fair value at ₹1,440 per share (range ₹893–₹1,489) against a market price of ₹1,748 (close of 23 Oct 2026): the estimate is 18% below the price. Estimate updated 23 October 2026. This is an estimated fair value based on stated assumptions, not investment advice.
Market price
₹1,748
close of 23 Oct 2026
Est. fair value
₹1,440
₹893–₹1,489
Estimate vs price
-17.6%
estimate below price
Above fair-value est.
Sun Pharma is India's largest drugmaker, selling generics at home and specialty medicines in the US. Its speciality dermatology and eye-care brands earn higher margins than commodity generics.
FY26
FY26
FY26
FY26
Over the last 3 years, revenue grew 10.0%/yr and profit grew 10.6%/yr. Over 9 years, revenue grew 7.1%/yr and profit 4.3%/yr.
Every ₹100 of shareholder money earned ₹13.8 in profit last year, vs a sector median of 10.6%.
It holds more cash than debt.
The market price is above our estimated fair-value range (based on stated assumptions).
About ₹103 of every ₹100 of reported profit turned into free cash (median, last 5 years); operating cash flow was positive in 5 of 5 years.
Intrynsic's multi-model valuation estimates Sun Pharmaceutical Industries Limited's fair value at ₹1,440 per share (range ₹893–₹1,489), last updated 23 October 2026. This is an estimate based on stated assumptions, not investment advice.
Sun Pharmaceutical Industries Limited trades at ₹1,748 against Intrynsic's estimated fair value of ₹1,440 - the market price is 18% above the estimate, i.e. above our estimated fair-value range. Different assumptions produce different estimates; see the model breakdown above.
Sun Pharmaceutical Industries Limited trades at about 36.5 times its latest annual earnings per share.
Sun Pharma is India's largest drugmaker, selling generics at home and specialty medicines in the US. Its speciality dermatology and eye-care brands earn higher margins than commodity generics.
Intrynsic runs 3 valuation models for Sun Pharmaceutical Industries Limited (DCF, EV/EBITDA, P/E Multiple) and blends them into one estimated fair-value range. Every assumption - growth, discount rate, terminal value - is shown openly on this page.
Disclaimer: Intrynsic provides educational and informational analysis only. Fair-value figures are estimates based on stated assumptions- they are not investment advice, research recommendations, or an offer to transact in any security. The models rely on assumptions (discount rates, growth, multiples) that may prove wrong and on past financials, which do not guarantee future results; prices also move on macro factors the models don't capture. Intrynsic is not a SEBI-registered investment adviser or research analyst. Markets carry risk; please do your own research or consult a registered adviser before making investment decisions. Prices shown may be delayed end-of-day values. Terms · Privacy